Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in the US in June 2022. In 2023, the company sold a 51% stake in its subsidiary Altamira Medica, which developed Bentrio for the prevention and treatment of allergic rhinitis.
Altamira Therapeutics Chairman and CEO Thomas Meyer commented, “We are very pleased to have achieved this major milestone in the protection of our intellectual property around Bentrio. Based on a drug free and preservative free formulation, Bentrio has demonstrated significant alleviation of the classic nasal symptoms of allergic rhinitis, including congestion, sneezing, itching, and rhinorrhea as well as of ocular symptoms. We look forward to making the product available in more and more countries, and in particular also to allergy sufferers in North America, through well established partners in the consumer health space.”
Bentrio is already available in certain countries outside of the US. Nuance Pharma has the rights to market Bentrio in a number of Asian markets, including China, Hong Kong, Macau, Singapore, Malaysia, Thailand, the Philippines, Indonesia, Vietnam, and Taiwan. Pharma Nordic has acquired the rights to market Bentrio in Norway, Sweden. and Denmark.
Read the Altamira Therapeutics press release
